215 related articles for article (PubMed ID: 28744107)
1. A cohort of French pediatric patients with primary immunodeficiencies: are patient preferences regarding replacement immunotherapy fulfilled in real-life conditions?
Pasquet M; Pellier I; Aladjidi N; Auvrignon A; Cherin P; Clerson P; Cozon GJN; Jaussaud R; Bienvenu B; Hoarau C
Patient Prefer Adherence; 2017; 11():1171-1180. PubMed ID: 28744107
[TBL] [Abstract][Full Text] [Related]
2. Does the route of immunoglobin replacement therapy impact quality of life and satisfaction in patients with primary immunodeficiency? Insights from the French cohort "Visages".
Bienvenu B; Cozon G; Hoarau C; Pasquet M; Cherin P; Clerson P; Hachulla E; Crave JC; Delain JC; Jaussaud R
Orphanet J Rare Dis; 2016 Jun; 11(1):83. PubMed ID: 27334100
[TBL] [Abstract][Full Text] [Related]
3. Measuring treatment satisfaction in patients with primary immunodeficiency diseases receiving lifelong immunoglobulin replacement therapy.
Nicolay U; Haag S; Eichmann F; Herget S; Spruck D; Gardulf A
Qual Life Res; 2005 Sep; 14(7):1683-91. PubMed ID: 16119180
[TBL] [Abstract][Full Text] [Related]
4. Quality of Life Differences for Primary Immunodeficiency Patients on Home SCIG versus IVIG.
Anterasian C; Duong R; Gruenemeier P; Ernst C; Kitsen J; Geng B
J Clin Immunol; 2019 Nov; 39(8):814-822. PubMed ID: 31673923
[TBL] [Abstract][Full Text] [Related]
5. Home-based subcutaneous immunoglobulin G replacement therapy under real-life conditions in children and adults with antibody deficiency.
Hoffmann F; Grimbacher B; Thiel J; Peter HH; Belohradsky BH;
Eur J Med Res; 2010 Jun; 15(6):238-45. PubMed ID: 20696632
[TBL] [Abstract][Full Text] [Related]
6. The influence of hospital-based intravenous immunoglobulin and home-based self-administrated subcutaneous immunoglobulin therapy in young children with primary immunodeficiency diseases on their parents' / caregivers' satisfaction.
Lechanska-Helman J; Sobocinska A; Jerzynska J; Stelmach I
Pediatr Int; 2020 Mar; 62(3):316-318. PubMed ID: 31880367
[TBL] [Abstract][Full Text] [Related]
7. Immunoglobulin replacement therapy in patients with immunodeficiencies: impact of infusion method on patient-reported outcomes.
Mallick R; Solomon G; Bassett P; Zhang X; Patel P; Lepeshkina O
Allergy Asthma Clin Immunol; 2022 Dec; 18(1):110. PubMed ID: 36566213
[TBL] [Abstract][Full Text] [Related]
8. Differences in Patient Demographics and Healthcare Costs of Patients with PIDD Receiving Intravenous or Subcutaneous Immunoglobulin Therapies in the United States.
Runken MC; Noone JM; Blanchette CM; Zacherle E; Howden R
Am Health Drug Benefits; 2019 Oct; 12(6):294-304. PubMed ID: 31908713
[TBL] [Abstract][Full Text] [Related]
9. Cost-minimization analysis of IgPro20, a subcutaneous immunoglobulin, in Japanese patients with primary immunodeficiency.
Igarashi A; Kanegane H; Kobayashi M; Miyawaki T; Tsutani K
Clin Ther; 2014 Nov; 36(11):1616-24. PubMed ID: 25236916
[TBL] [Abstract][Full Text] [Related]
10. Patient experience with subcutaneous immunoglobulin 20%, Ig20Gly, for primary immunodeficiency diseases: a prespecified post hoc analysis of combined data from 2 pivotal trials.
Meckley LM; Wu Y; Ito D; Berner T; McCoy B; Yel L
BMC Immunol; 2020 May; 21(1):24. PubMed ID: 32366233
[TBL] [Abstract][Full Text] [Related]
11. Children and adults with primary antibody deficiencies gain quality of life by subcutaneous IgG self-infusions at home.
Gardulf A; Nicolay U; Math D; Asensio O; Bernatowska E; Böck A; Costa-Carvalho BT; Granert C; Haag S; Hernández D; Kiessling P; Kus J; Matamoros N; Niehues T; Schmidt S; Schulze I; Borte M
J Allergy Clin Immunol; 2004 Oct; 114(4):936-42. PubMed ID: 15480339
[TBL] [Abstract][Full Text] [Related]
12. Czech Hizentra Noninterventional Study With Rapid Push: Efficacy, Safety, Tolerability, and Convenience of Therapy With 20% Subcutaneous Immunoglobulin.
Milota T; Bloomfield M; Kralickova P; Jilek D; Novak V; Litzman J; Posova H; Mrazova L; Poloniova J; Prucha M; Rozsival P; Rauschova V; Philipp G; Sediva A
Clin Ther; 2019 Nov; 41(11):2231-2238. PubMed ID: 31564514
[TBL] [Abstract][Full Text] [Related]
13. Treatment Satisfaction with Subcutaneous Immunoglobulin Replacement Therapy in Patients with Primary Immunodeficiency: a Pooled Analysis of Six Hizentra® Studies.
Mallick R; Jolles S; Kanegane H; Agbor-Tarh D; Rojavin M
J Clin Immunol; 2018 Nov; 38(8):886-897. PubMed ID: 30465179
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and quality of life assessment in the use of subcutaneous immunoglobulin treatment for children with primary immunodeficiency disorder.
Sarı G; Güven Bilgin B; Yılmaz E; Aytac G; Edeer Karaca N; Aksu G; Kutukculer N
Eur Ann Allergy Clin Immunol; 2021 Jul; 53(4):177-184. PubMed ID: 33191716
[No Abstract] [Full Text] [Related]
15. Prognostic factors for health-related quality of life in adults and children with primary antibody deficiencies receiving SCIG home therapy.
Gardulf A; Borte M; Ochs HD; Nicolay U;
Clin Immunol; 2008 Jan; 126(1):81-8. PubMed ID: 17964220
[TBL] [Abstract][Full Text] [Related]
16. Safety and efficacy of home-based subcutaneous immunoglobulin G in elderly patients with primary immunodeficiency diseases.
Stein MR; Koterba A; Rodden L; Berger M
Postgrad Med; 2011 Sep; 123(5):186-93. PubMed ID: 21904101
[TBL] [Abstract][Full Text] [Related]
17. Intravenous and subcutaneous immunoglobulin replacement: a two-way road. Optimizing healthcare quality in patients with primary immunodeficiencies.
Soler-Palacín P; Gasó-Gago I; Fernández-Polo A; Martín-Nalda A; Oliveras M; Martinez-Cutillas J; Figueras C
J Clin Immunol; 2014 Nov; 34(8):1015-7. PubMed ID: 25190197
[TBL] [Abstract][Full Text] [Related]
18. Switch from intravenous to subcutaneous immunoglobulin in CIDP and MMN: improved tolerability and patient satisfaction.
Hadden RD; Marreno F
Ther Adv Neurol Disord; 2015 Jan; 8(1):14-9. PubMed ID: 25584070
[TBL] [Abstract][Full Text] [Related]
19. Economic evaluation of immunoglobulin replacement in patients with primary antibody deficiencies.
Beauté J; Levy P; Millet V; Debré M; Dudoit Y; Le Mignot L; Tajahmady A; Thomas C; Suarez F; Pellier I; Hermine O; Aladjidi N; Mahlaoui N; Fischer A;
Clin Exp Immunol; 2010 May; 160(2):240-5. PubMed ID: 20041884
[TBL] [Abstract][Full Text] [Related]
20. Evaluating dose ratio of subcutaneous to intravenous immunoglobulin therapy among patients with primary immunodeficiency disease switching to 20% subcutaneous immunoglobulin therapy.
Krishnarajah G; Lehmann JK; Ellman B; Bhak RH; DerSarkissian M; Leader D; Bullinger AL; Sheng Duh M
Am J Manag Care; 2016 Oct; 22(15 Suppl):s475-s481. PubMed ID: 27849353
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
